Fremanezumab
- Generic Name
- Fremanezumab
- Brand Names
- Ajovy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1655501-53-3
- Unique Ingredient Identifier
- PF8K38CG54
- Background
Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. Along with other recently approved anti-CGRP therapies such as galcanezumab, erenumab, and the oral CGRP antagonist ubrogepant, fremanezumab represents an important step forward in the treatment and prevention of migraine headaches.
- Indication
Fremanezumab is indicated for the preventative treatment of migraine in adults.
- Associated Conditions
- Migraine
- Associated Therapies
- -
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 476
- Registration Number
- NCT04530110
- Locations
- 🇮🇹
Teva Investigational Site 30230, Firenze, Italy
🇮🇹Teva Investigational Site 30239, Milano, Italy
🇮🇹Teva Investigational Site 30228, Milano, Italy
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years of Age
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 298
- Registration Number
- NCT04464707
- Locations
- 🇺🇸
Teva Investigational Site 14322, Los Angeles, California, United States
🇺🇸Teva Investigational Site 14361, Sacramento, California, United States
🇺🇸Teva Investigational Site 14319, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.